Agenus Stock Price, News & Analysis

Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced that Dr. Garo Armen and Dr. Steven O’Day will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:30 AM EST. The event will take place at the New York Marriott Marquis from June 8-10. One-on-one meetings with investors will also be available. A webcast of the chat can be accessed for 90 days post-event. Agenus focuses on therapies that engage the immune system to combat cancer and infections.

Agenus (NASDAQ: AGEN) has announced its Annual Shareholders Meeting set for June 8, 2022, at 3:30 p.m. ET, to be held virtually. Shareholders can register from 3:15 p.m. ET via a control number found in proxy materials. The meeting will be accessible in listen-only mode for non-shareholders. Agenus focuses on immuno-oncology, developing therapies that engage the immune system against cancer and infections, utilizing a range of advanced platforms and facilities.

Agenus Inc. (NASDAQ: AGEN) announces botensilimab's late-breaking presentation at the ESMO World Congress on Gastrointestinal Cancer, focusing on treating heavily pretreated MSS colorectal cancer. The company also reveals a strategic plan to cut operating costs by 20% in 2022. Positive clinical responses were highlighted, with botensilimab and balstilimab showing efficacy in difficult-to-treat patients. Agenus aims to accelerate development and prioritize high-potential programs while enhancing operational efficiencies through advanced technologies.

Agenus Inc. (NASDAQ: AGEN) announced significant clinical advancements in its immuno-oncology pipeline. The company is set to initiate Phase 2 trials for botensilimab targeting colorectal, melanoma, and pancreatic cancers, with data updates expected in Q3. AGEN1571 trials will commence following its presentation at AACR, while AGEN2373 is progressing, evidenced by a $5 million milestone payment from Gilead, with potential future payments up to $570 million. Financially, Agenus reported $26 million in revenue for Q1 2022, an increase of $14 million year-over-year, and a net loss of $51 million.

Agenus (NASDAQ: AGEN) will release its Q1 2022 financial results on May 10, 2022, before market opening. The company focuses on immuno-oncology, developing therapies that leverage the immune system against cancer. A conference call and webcast are scheduled for the same day at 8:30 a.m. ET to discuss results and offer a corporate update. The call can be accessed via dial-in numbers provided, and a replay will be available on the company's website. For more information, visit www.agenusbio.com.

Agenus Inc. (Nasdaq: AGEN) announced preclinical data presentation of AGEN1571, a novel anti-ILT2 antibody, at the AACR Annual Meeting on April 8-12, 2022. The data highlight robust adaptive and innate immune responses, showing AGEN1571's superior performance compared to existing clinical-stage competitors. Key findings include a ~10-fold higher binding affinity and complete blockade of ILT2-ligand interactions. The company has cleared its Investigational New Drug (IND) application, paving the way for upcoming clinical trials, further enhancing its immuno-oncology pipeline.

Agenus Inc. (NASDAQ: AGEN) received a $5M clinical milestone payment for AGEN2373, a CD137 agonist, as part of its ongoing Phase 1b study in melanoma patients resistant to prior anti-PD-1 therapy. The combination of AGEN2373 and botensilimab has shown promising preclinical results, boosting tumor control. AGEN2373 is well tolerated, with no liver toxicity reported. Gilead holds an exclusive option to license AGEN2373, while Agenus can opt-in to share development costs, allowing for a potential 50:50 profit split and co-commercialization in the U.S.

Agenus (NASDAQ: AGEN) announced a collaboration with Targovax to develop TG mutant KRAS cancer vaccines combined with Agenus’s QS-21 STIMULON adjuvant. This partnership may lead to an exclusive commercial agreement based on successful clinical trial outcomes. The TG vaccines target mutations in the RAS gene, responsible for approximately 30% of cancers. Targovax has received significant funding to advance the TG program, while QS-21 STIMULON is recognized for its effectiveness in boosting immune responses. Positive clinical results could yield tiered royalties for Agenus.

Agenus Inc. (NASDAQ: AGEN) reported its 2021 financial results, ending with $307 million in cash. The company advanced key clinical programs, notably botensilimab, which has shown promise in treating multiple cold, treatment-resistant cancers. Phase II studies are set to begin for melanoma, MSS-colorectal, and pancreatic cancers, aiming to outperform traditional therapies. Revenue surged to $296 million in 2021, driven by license fees and milestone payments, despite a net loss of $29 million. The firm is strategically positioned for future growth, backed by significant partnerships and proprietary technology.